Observational analysis evaluates chemotherapy efficacy in metastatic colorectal cancer, suggesting optimal treatment combinations.
Colorectal cancer (CRC) is one of the leading causes of cancer-related mortality, with rat sarcoma (RAS) and proto-oncogene B-raf (BRAF) mutations associated with worse prognosis in metastatic settings. Despite advances in treatment, the optimal chemotherapy backbone combined with bevacizumab in RAS/BRAF-mutant metastatic CRC remains unclear. Our study aimed to investigate the best chemotherapy backbone in this patient group.
No takes yet. Share an insight, caveat, or question.
Topal et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: